Clinical Trials
66 trialsNCT07618910 2026-06-01
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT07452601 2026-05-28
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Recruiting
NCT06535607 2026-05-26
eVOLVE-02
AstraZeneca
Phase 2 Recruiting
NCT07559045 2026-04-30
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Recruiting
NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT07481058 2026-03-20
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03322267 2026-03-06
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
National Taiwan University Hospital
Phase 2 Completed
NCT07039162 2026-02-27
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
China Medical University Hospital
Phase 2 Recruiting
NCT07403435 2026-02-11
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT06281886 2025-11-17
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05880082 2025-08-24
PPIO-004-EC001
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Completed
NCT03797625 2025-07-23
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Completed
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT06446726 2025-06-06
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
Sichuan University
Phase 2 Recruiting
NCT04804696 2025-02-21
Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Terminated
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT05490719 2024-05-21
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03964753 2023-10-10
NTNC
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05302011 2023-10-10
Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT06006650 2023-08-23
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Tang-Du Hospital
Phase 2 Recruiting
NCT05281003 2023-07-13
HYPERION
Fudan University
Phase 2 Recruiting
NCT04389177 2023-04-10
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT02976909 2023-02-17
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05522894 2022-08-31
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
ChineseAMS
Phase 2 Unknown
NCT05469061 2022-07-21
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT03946969 2022-07-19
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT00573131 2022-06-22
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Boston Scientific Corporation
Phase 2 Terminated
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT04390958 2022-03-15
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
Phase 2 Unknown
NCT01670409 2022-01-03
Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer
Shantou University Medical College
Phase 2 Completed
NCT05007145 2021-12-21
REVO
Fujian Cancer Hospital
Phase 2 Unknown
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT04063683 2021-08-24
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Henan Cancer Hospital
Phase 2 Unknown
NCT03791905 2021-03-23
PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT04225364 2021-02-02
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
Guangzhou Institute of Respiratory Disease
Phase 2 Completed
NCT03377400 2020-12-17
Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer
Samsung Medical Center
Phase 2 Unknown
NCT02812641 2019-03-11
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC
National Taiwan University Hospital
Phase 2 Unknown
NCT03579004 2018-07-06
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Phase 2 Unknown
NCT03126708 2018-01-04
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Unknown
NCT00069953 2017-02-17
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02969473 2016-11-21
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT01854749 2016-02-23
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Fudan University
Phase 2 Completed
NCT02665702 2016-01-28
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas
Fudan University
Phase 2 Unknown
NCT00397904 2015-11-25
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02325986 2015-11-20
Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT00109850 2015-11-18
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT02586753 2015-10-26
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
Mianyang Central Hospital
Phase 2 Unknown